Adalimumab for the treatment of hidradenitis suppurativa: evaluation of clinical response and impact on inflammatory markers
European Journal of Dermatology · 2025
DOI: 10.1684/ejd.2025.4903 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Dermatology, 2025. Verfasst von Carlota Arce und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medicine Faculty of Porto University, Alameda Prof. Hernâni Monteiro 4200-319 Porto, Portugal. Hauptthemen laut MEDLINE: Adalimumab, Hidradenitis Suppurativa, Anti-Inflammatory Agents.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicine Faculty of Porto University, Alameda Prof. Hernâni Monteiro 4200-319 Porto, Portugal.
- Dermatology Department, Centro Hospitalar e Universitário de Santo António, Largo do Prof. Abel Salazar 4099-001 Porto, Portugal.
Zitieren
APA
Arce, C., Lobo, I., Rodrigues, A., Machado, S., Nogueira, M., & Linhares, P. (2025). Adalimumab for the treatment of hidradenitis suppurativa: evaluation of clinical response and impact on inflammatory markers. European Journal of Dermatology. https://doi.org/10.1684/ejd.2025.4903
Vancouver
Arce C, Lobo I, Rodrigues A, Machado S, Nogueira M, Linhares P. Adalimumab for the treatment of hidradenitis suppurativa: evaluation of clinical response and impact on inflammatory markers. European Journal of Dermatology. 2025. doi:10.1684/ejd.2025.4903
BibTeX
@article{Arce2025,
author = {Arce, Carlota and Lobo, Inês and Rodrigues, Alexandra and Machado, Susana and Nogueira, Miguel and Linhares, Paulo},
title = {Adalimumab for the treatment of hidradenitis suppurativa: evaluation of clinical response and impact on inflammatory markers},
journal = {European Journal of Dermatology},
year = {2025},
doi = {10.1684/ejd.2025.4903}
}
EUVIMED